Capsida Biotherapeutics
PrivateLast Round
Strategic
Feb 23, 2023
Total Funding Raised
$185M
Company Overview
Capsida Biotherapeutics operates in Healthcare & Life Sciences and is based in Thousand Oaks, California. Its latest recorded funding round was a Strategic round in February 2023.
Capsida Biotherapeutics is a biotechnology company that develops targeted gene therapies aimed at treating debilitating and life-threatening genetic disorders through an advanced adeno-associated virus (AAV) engineering platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Capsida Biotherapeutics Comparables
Compare Capsida Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Latus Bio | 89% | |
| Coave Therapeutics | 85% | |
| Apertura Gene Therapy | 85% |
For institutional investors. Book with your work email.
Capsida Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Feb 23, 2023 | ||||
| Strategic | Jan 4, 2023 | ||||
| Series A | Apr 29, 2021 |
For institutional investors. Book with your work email.
Capsida Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Westlake Village BioPartners | Series A |
| Versant Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 20, 2026
Monthly visitors increased 77% MoM.
- May 14, 2025
Presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingOct 15, 2026
Capsida Biotherapeutics, Inc. raises more than $165M during a period of significant growth and secures partnerships with AbbVie and Lilly.
For institutional investors. Book with your work email.
Capsida Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Capsida Biotherapeutics's valuation, stock price, and market status.
Is Capsida Biotherapeutics a public or private company?
Capsida Biotherapeutics is a private company.
What is the current stock price of Capsida Biotherapeutics?
Capsida Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Capsida Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Capsida Biotherapeutics worth (valuation)?
Valuation information for Capsida Biotherapeutics is not publicly available.
Can I buy Capsida Biotherapeutics stock?
Capsida Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Capsida Biotherapeutics's last funding round?
Capsida Biotherapeutics's most recent funding round was Strategic on February 23, 2023.
Who are the main investors in Capsida Biotherapeutics?
Key investors in Capsida Biotherapeutics include Westlake Village BioPartners, Versant Ventures.
Will Capsida Biotherapeutics IPO soon?
No public IPO plans have been announced for Capsida Biotherapeutics.
How can I track Capsida Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Capsida Biotherapeutics's shares on secondary markets.